Co-organised by Parkway Shanghai Hospital, University of Hong Kong, Japan's Keio University, Shanghai First People's Hospital, and the Wu Mengchao Foundation the forum also marked the launch of the hospital’s International Hepatobiliary and Pancreatic Diagnosis and Treatment Centre.

In his welcome remarks, Dr Kenneth Tsang, Regional CEO of IHH Healthcare North Asia and CEO of Gleneagles Hospital Hong Kong, highlighted the growing complexity of hepatobiliary and pancreatic diseases and the need for closer collaboration. He shared how the IHH Healthcare North Asia network is strengthening knowledge exchange and accelerating the use of innovative treatments to improve patient outcomes.

Dr Tsang cited Histotripsy, a non-invasive liver cancer treatment introduced at Gleneagles Hospital Hong Kong in 2025, as an example of how innovation can change the way complex diseases are treated.

“By working together across our network, we can bring new solutions to patients faster and raise the standard of care across the region,” he said.

The newly launched Centre will serve as a multidisciplinary hub, bringing together expertise across surgery, gastroenterology, oncology and critical care. Supported by IHH Healthcare’s multinational network, it aims to deepen international collaboration, tackle complex cases and deliver more comprehensive care for patients across Asia.